The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Mar. 08, 2021
Applicant:

Medtronic, Inc., Minneapolis, MN (US);

Inventors:

Randal C. Schulhauser, Phoenix, AZ (US);

Avram Scheiner, Vadnais Heights, MN (US);

Linnea R. Lentz, Stacy, MN (US);

Assignee:

Medtronic, Inc., Minneapolis, MN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61N 1/36 (2006.01); A61B 5/318 (2021.01); A61B 5/053 (2021.01); A61N 1/05 (2006.01); A61B 5/00 (2006.01); A61B 5/08 (2006.01);
U.S. Cl.
CPC ...
A61N 1/3606 (2013.01); A61B 5/053 (2013.01); A61B 5/0816 (2013.01); A61B 5/318 (2021.01); A61B 5/4818 (2013.01); A61N 1/0548 (2013.01); A61N 1/0551 (2013.01); A61N 1/3614 (2017.08); A61B 2562/0219 (2013.01);
Abstract

Apnea events may be detected based on a primary biomarker, e.g., respiration, in the one or more physiological signals. The apnea events may be characterized as one of an obstructive sleep apnea (OSA) event, a central sleep apnea (CSA) event, or a combination OSA/CSA event based on a secondary biomarker, e.g., a frequency spectrum or a morphology of the respirations in the one or more physiological signals. A first electrical stimulation may be provided to treat OSA in response to a first one or more of the apnea events being characterized as OSA events. A second electrical stimulation may be provided to treat CSA in response to a second one or more of apnea events being characterized as CSA events. A third electrical stimulation may be provided to treat combination OSA/CSA in response to a third one or more of the apnea events being characterized as combination OSA/CSA events.


Find Patent Forward Citations

Loading…